Table 1.
Baseline characteristics.
| R-Chemo group (N = 18) | Chemo only group (N = 17) | Entire cohort (N = 35) | |
|---|---|---|---|
| Age (median, range) | 42 years (20–70) | 42 years (21–74) | 44 years (20–74) |
| Sex | |||
| Male | 9 (50%) | 11 (64.7%) | 20 (57%) |
| Female | 9 (50%) | 6 (36.3%) | 15 (43%) |
| Race | |||
| White | 15/17 (88.2%)* | 16/17 (94.1%) | 31/34 (91.2%)* |
| Black | 1/17* (5.9%) | 1/17 (5.9%) | 2/34 (5.9%)* |
| Other | 1/17* (5.9%) | 0/17 (0%) | 1/34 (2.9%)* |
| Ann Arbor Stage | |||
| I | 2 (11.1%) | 2 (11.8%) | 4 (11.4%) |
| II | 3 (16.7%) | 0 (0%) | 3 (8.6%) |
| III | 1 (5.6%) | 2 (11.8%) | 3 (8.6%) |
| IV | 12 (66.7%) | 13 (76.5%) | 25 (71.4%) |
| Elevated lactate dehydrogenase | 14/17 (82.4%)* | 11/14 (78.6%)* | 25/31 (80.6%)* |
| Elevated uric acid | 11/17 (61.1%)* | 4/11 (36.4%)* | 15/28 (53.6%)* |
| CNS involvement | 5/18 (27.8%) | 5/12 (41.7%)* | 10/30 (33.3%)* |
| Bone marrow involvement | 8/16 (50%)* | 8/16 (50%)* | 16/32 (50.0%)* |
| Performance status | |||
| 0 | 0/18 (0%) | 2/14 (14.3%)* | 2/32 (6.2%)* |
| 1 | 14/18 (77.8%) | 9/14 (64.3%)* | 23/32 (71.9%)* |
| 2 | 3/18 (16.7%) | 1/14 (7.1%)* | 4/32 (12.5%)* |
| 3 | 1/18 (5.6%) | 1/14 (7.1%)* | 2/32 (6.2%)* |
| 4 | 0/18 | 1/14 (7.1%)* | 1/32 (3.1%)* |
| IPI | |||
| 0 | 2/17 (11.8%)* | 0 (0%) | 2/30 (6.7%)* |
| 1 | 1/17 (5.9%)* | 4/13 (30.8%)* | 5/30 (16.7%)* |
| 2 | 6/17 (35.3%)* | 3/13 (23.1%)* | 9/30 (30.0%)* |
| 3 | 4/17 (23.5%)* | 4/13 (30.8%)* | 8/30 (26.7%)* |
| 4 | 3/17 (17.6%)* | 2/13 (15.4%)* | 5/30 (16.7%)* |
| 5 | 1/17 (5.9%)* | 0 (0%) | 1/30 (3.3%)* |
*
Denominator reflects missing data.
CNS, central nervous system; IPI, International Prognostic Index.